<DOC>
	<DOCNO>NCT02786212</DOCNO>
	<brief_summary>Cardiac surgery cardiopulmonary bypass ( CPB ) provoke systemic inflammatory response often lead dysfunction major organ . Activation contact system , endotoxemia , surgical trauma , ischemic reperfusion injury possible trigger inflammation . Previous study demonstrate pro-inflammatory cytokine play important role process . However , little known susceptibility splanchnic organ ischemic reperfusion injury . Although incidence intestinal complication report low , in-hospital mortality patient high 15 % 63 % . Dexmedetomidine , highly selective α2-adrenergic agonist , reduce consumption sedative antinociceptive drug provide sufficient sedative effect minimal respiratory side effect . In addition , dexmedetomidine gradually gain popularity field critical care . Preemptive administration dexmedetomidine show protective inflammation , intestinal , renal , myocardial injury animal human study . Dexmedetomidine also use anesthetic adjuvant surgery offer good perioperative hemodynamic stability intraoperative anesthetic-sparing effect . Perioperative use dexmedetomidine reduce intestinal hepatic injury hepatectomy inflow occlusion general anesthesia . However , whether exert protective effect above-mentioned organ , especially intestine , cardiac surgery remain unclear . The aim study evaluate effect dexmedetomidine intestinal , hepatic , organ injury patient receive cardiac surgery CPB . In double-blinded randomized control study , serum diamine oxidase activity , sensitive specific marker detection intestinal injury , take primary endpoint . Other parameter reflect function liver ( AST/ALT ) , lung ( lung injury score CC-16 ) , kidney ( BUN/Cre ) , heart ( CK-MB/Troponin T ) , biomarker endothelial injury ( endocan ) also determine . Besides , microcirculation parameter measure Cytocam® near-infrared spectroscopy ( NIRS ) use estimate protective effect dexmedetomidine microcirculation . The variable collect perioperatively follow 3 day surgery . Clinical outcome parameter follow 3 month surgery .</brief_summary>
	<brief_title>The Effects Dexmedetomidine Intestine Other Organ Damages After Cardiac Surgeries</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Nonemergent cardiac surgery cardiopulmonary bypass leave ventricle ejection fraction &lt; 40 % acute myocardial infarction within 3 month angina within 48 hour surgery COPD previous history inflammatory bowel disease diarrhea within 7 day surgery previous cardiac surgery receive nonpharmacological cardiac supportive management previous pulmonary embolism previous deep vein thrombosis allergic dexmedetomidine refractory bradycardia ( HR &lt; 60/min )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>